You are here: Home » International » News » Others
Business Standard

AstraZeneca resumes Oxford Covid vaccine trial after UK green signal

The late-stage trials of the experimental vaccine, one of the most advanced in development, were suspended this week after an illness in a study subject in Britain

Topics
AstraZeneca | Coronavirus Vaccine | UK

Reuters  |  London 

AstraZeneca, pharma, coronavirus, vaccine
The company said it could not disclose further medical information.

British clinical trials for the and Oxford University vaccine have resumed following confirmation by the Medicines Health Regulatory Authority (MHRA) that it was safe to do so, the company said on Saturday.

The late-stage trials of the experimental vaccine, one of the most advanced in development, were suspended this week after an illness in a study subject in Britain.

"The standard review process triggered a voluntary pause to vaccination across all global trials to allow review of safety data by independent committees, and regulators," said.

"The committee has concluded its investigations and recommended to the MHRA that trials in the are safe to resume."

The company said it could not disclose further medical information.

"All trial investigators and participants will be updated with the relevant information and this will be disclosed on global clinical registries, according to the clinical trial and regulatory standards."

 

 

 

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Sat, September 12 2020. 19:57 IST
RECOMMENDED FOR YOU
.